Injectable drug for advanced digestive system cancers
Part of Cancer, Digestive system clinical trials.
This trial tests an investigational drug called ALK-N001 given as an injection for people with advanced gastrointestinal cancers. It aims to see if the drug can slow or stop tumor growth, and if it's safe to take.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a type of gastrointestinal cancer, such as esophageal, colorectal, or other digestive system cancer, that has spread or cannot be removed by surgery.
- Standard treatments have either stopped working or caused too many side effects.
- You should be generally able to care for yourself (up and about) and have a life expectancy of at least 3 months.
- Your blood counts, liver, kidney, and heart function need to be within acceptable ranges.
- You cannot have certain health conditions, such as severe lung disease, unstable brain metastases, or recent heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug called ALK-N001 for people with advanced solid tumors that have not responded to standard treatment or cannot tolerate it. It aims to see if the drug can help shrink tumors and improve outcomes.
This trial tests a new drug, ALK201, in people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and can shrink tumors.
This trial tests a new drug called ALK202 for people with advanced solid tumors that have not responded to other treatments. The study aims to see if the drug is safe and to find the best dose.
This trial tests a new drug called ALK201 combined with an immunotherapy drug (ivonescimab) for people with squamous non-small cell lung cancer. The goal is to see if this combination can shrink tumors and is safe.
This trial tests an investigational cell therapy called GKL-006Allo for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this therapy can help shrink or slow the growth of tumors.
This study tests a new drug called ALK202, given with other medicines, to see if it is safe and works for people with non-small cell lung cancer. It targets certain proteins on cancer cells, and doctors will check your tumor for those markers to see if you might benefit.
Hear when a new Advanced Gastrointestinal Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.